MIDEAS antisense RNA 1 (MIDEAS-AS1)

MIDEAS antisense RNA 1 (MIDEAS-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the MIDEAS gene, and is primarily localized in the nucleus[2]. It acts as a tumor suppressor in triple-negative breast cancer (TNBC), where its expression is markedly reduced compared to other breast cancer types. Low levels of MIDEAS-AS1 are associated with poor prognosis. Experimental data show that overexpression of MIDEAS-AS1 inhibits cell proliferation, reduces cell mobility, promotes apoptosis, and arrests the cell cycle in G1 phase in TNBC cell lines and organoids. Mechanistically, MIDEAS-AS1 interacts directly with the nuclear matrix-associated protein MATR3, which leads to upregulation of tumor-suppressive genes (like NCALD) and inhibition of the NF-κB signaling pathway. It also modulates EMT-related markers, decreasing levels of N-cadherin, vimentin, fibronectin and MMP9, while upregulating E-cadherin, which collectively suppresses metastasis. MIDEAS-AS1 does not appear to regulate its sense gene MIDEAS. Its demonstrated tumor-suppressive functions and link to prognosis highlight its potential role as a biomarker and future therapeutic target in TNBC[2]. There is no evidence indicating any errors, ambiguity, or misspelling associated with MIDEAS-AS1 in the scientific literature. It is not a classical "receptor," "enzyme," or small-molecule drug target, but is increasingly recognized as a valid molecular target for oncology biomarker and lncRNA-targeting research. Experimental drugs targeting MIDEAS-AS1 are not currently reported in the literature.

Other names

MIDEAS-AS1